Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupting glucose-derived cholesterol synthesis in liver as revealed by the [U-C(6)]-d-glucose tracer in mice.

"Conflict of interest We declare no conflict of interest in performing, presenting, discussing and concluding stable isotope-labeled biomarker metabolite profiles reported in this manuscript. None of the authors are or have been involved in the production or sales of the tracer glucose substrate, valproic acid, any chemical or product used to perform these studies. Furthermore the reported studies have been performed as a collaborative research agreement with no funds transferred between the institutions participating in the experiments and the results are aimed at improving drug toxicology assessments for the benefit of the Public."

"We thank Tamas F. Boros for coordinating metabolite, enzyme convention (EC) names, and numbers for human enzyme isoforms with the International KEGG and BRENDA databases, Dale Chenoweth for final edit of the manuscript, and Gene White, Carrie Moland and Bionetic Animal Care Staff for work during this animal study. Financial or Material Support: All sources of funding for these studies have been drawn internally within the participating institutions as a service to governments of the United States and the United Kingdom in order to cover base salaries and material costs. More specifically, this work was performed pursuant to a Material Transfer Agreement by and between SiDMAP, LLC and the National Institutes of Health, the Food and Drug Administration, and the Centers for Disease Control and Prevention. No funds were transferred between Institutions for this work."